Clinical trials: Caffeine, open to volunteers
- Drug or intervention Caffeine
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Ulcerative Colitis, Crohn's Disease
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
This is an open-label, single group, 2-period, Phase 1, single-arm study. The primary purpose of this study is to investigate the effects of duvakitug on the pharmacokinetics of selected cytochrome P450 substrates in adult…
- Trial name
- NCT07923383
- Testing
- Duvakitug
- Volunteers
- 25 people
- Sponsor
- Sanofi
Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
The goal of this clinical trial is to learn if Oleogel-S10 gel works to treat skin wounds from two types of inherited epidermolysis bullosa (EB): junctional EB (JEB) or dystrophic EB (DEB) in the Japanese population.
- Conditions
- Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
- Trial name
- REVIVE (NCT06917690)
- Testing
- Oleogel-S10
- Where
- 6 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Rheumatoid Arthritis, Osteoarthritis Shoulder
Tornier HRS (Humeral Reconstruction System) Study (REVIVE)
This is an international, single arm, multicenter, prospective follow-up, non-significant risk, Post-Market Clinical Follow-up (PMCF) study.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis Shoulder, Fractures Humerus, Avascular Necrosis
- Trial name
- REVIVE (NCT05500066)
- Testing
- Tornier HRS (HUMERAL RECONSTRUCTION SYSTEM) shoulder system
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Stryker Trauma and Extremities
Healthy Adult Participants
A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects
This is a Phase 1, fixed-sequence, multiple-dose study in approximately 42 healthy adult participants. The study will be conducted in two parts.
- Trial name
- NCT07881224
- Testing
- Fosmanogepix, The medicine cocktail (caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan and midazolam), Probe substrates (repaglinide, rosuvastatin, and digoxin)
- Where
- Netherlands
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Hemorrhagic Shock, Trauma
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam
The purpose of this study is to demonstrate safety, effectiveness and benefit-risk profile of ResQFoam for the inhospital treatment of exsanguinating, intraabdominal haemorrhage due to trauma in patients where emergent laparotomy…
- Conditions
- Hemorrhagic Shock, Trauma, Exsanguinating Hemorrhage, Shock; Traumatic
- Trial name
- REVIVE (NCT02880163)
- Testing
- ResQFoam
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Arsenal Medical, Inc.
Acute Coronary Syndrome
AngelMed Guardian® System PMA Post Approval Study
500 Patients (minimum) will be enrolled following commercial implant. Will be treated by their physicians using the standard of care.
- Trial name
- NCT05412927
- Testing
- PMA P150009 AngelMed Guardian® System
- Where
- 18 sites in United States
- Volunteers
- 500 people
- Sponsor
- Angel Medical Systems
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Heart Failure
Monitoring Oedema in Heart Failure to Improve Function and Reduce Hospitalisation Risk
This study will evaluate the Heartfelt device, a novel, passive monitoring system that detects early signs of fluid build-up in patients (oedema) with heart failure by measuring changes in foot and lower leg volume through…
- Trial name
- ME-HF (NCT07067658)
- Testing
- Installation of Heartfelt Device, Enhanced Standard care, Questionnaires
- Where
- 18 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Heartfelt Technologies
Non-small Cell Lung Cancer
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
This study is designed as a multi-cohort trial based on various patient biomarkers study with the potential to include new study treatment in the future.
- Trial name
- REVIVE (NCT07279935)
- Testing
- Osimertinib+cisplatin or carboplatin + pemetrexed Edit
- Where
- 32 sites in China
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Obesity, Overweight
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight
The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.
- Trial name
- NCT07710768
- Testing
- UBT251, Cocktail (Warfarin/Caffeine/Midazolam)
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obese, Overweight Adults
A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults
The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults.
- Conditions
- Obese, Overweight Adults, Obese Adults, Body Weight Control
- Trial name
- NCT07363148
- Testing
- MB-1
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Arrae
Common Cold/Flu, Nasal Congestion
Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults
Phase III clinical trial to evaluate the efficacy and safety of a fixed-dose combination of 1000 mg dipyrone monohydrate + 60 mg caffeine + 4 mg chlorpheniramine maleate in improving symptoms of the common cold and flu in adults.
- Conditions
- Common Cold/Flu, Nasal Congestion, Nasal Obstruction
- Trial name
- PANAMA (NCT07626437)
- Testing
- dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg, dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg
- Where
- 15 sites in Brazil
- Volunteers
- 620 people
- Sponsor
- Brainfarma Industria Química e Farmacêutica S/A
Active Ulcerative Colitis
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121).
- Trial name
- NCT07665723
- Testing
- Afimkibart, Caffeine, Warfarin
- Where
- 18 sites in United States, Belgium and 3 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how…
- Trial name
- NCT07883590
- Testing
- LY3873862, CYP450 Drug Cocktail
- Where
- 4 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY4515100 in Healthy Participants
The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines.
- Trial name
- NCT07339722
- Testing
- LY4515100 via SAD, LY4515100 via MAD, LY4515100
- Where
- 2 sites in United States
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Heart Failure
A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)
The purpose of this clinical study is to evaluate the efficacy and safety of intramyocardial injection of human induced pluripotent stem cell-derived cardiomyocyte injection (HiCM-188) in patients with advanced heart failure…
- Trial name
- REVIVE-HEART (NCT07496372)
- Testing
- HiCM-188 therapy, CABG surgery
- Where
- China
- Volunteers
- 80 people
- Sponsor
- HELP Therapeutics Co., Ltd.
COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations
The REVIVE Pivotal Study
The goal of this study is to test whether a new treatment called the Ryme Medical Targeted Lung Denervation (TLD) Catheter is safe and effective for people with moderate to severe chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations, COPD Patients, COPD Acute Exacerbation
- Trial name
- REVIVE (NCT07361653)
- Testing
- Ryme TLD
- Volunteers
- 300 people
- Sponsor
- Ryme Medical, Inc.